[Form 4] Vir Biotechnology, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Vir Biotechnology (VIR): Form 4 insider transaction — SVF Endurance (Cayman) Limited, an affiliate of SoftBank Vision Fund, reported open‑market sales executed under a Rule 10b5-1 trading plan. On 10/15/2025, it sold 16,671 shares of common stock at a weighted average price of $6.0702. On 10/16/2025, it sold 12,844 shares at a weighted average price of $6.1014. Following these transactions, indirect beneficial ownership is reported as 15,340,494 shares. The filing notes the weighted‑average price ranges for each date and offers to provide full trade‑by‑trade detail upon request.

Insights

Equity market structure analyst

Planned, incremental sales with minimal signaling; neutral impact.

The filing shows two small open‑market sales by SVF Endurance (Cayman) Limited on 10/15/2025 and 10/16/2025 under a Rule 10b5‑1 plan. Volumes were modest relative to the reported indirect holding.

Weighted‑average prices were $6.0702 and $6.1014, with disclosed price ranges per SEC guidance. Indirect beneficial ownership after the reported trades is 15,340,494 shares.

The use of a 10b5‑1 plan indicates pre‑scheduled execution mechanics. Actual market impact depends on ongoing holder decisions; no forward timing is indicated in the excerpt.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SVF Endurance (Cayman) Ltd

(Last) (First) (Middle)

C/O WALKERS CORP LTD., 190 ELGIN AVENUE

(Street)

GEORGE TOWN E9 KY1-9008

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/15/2025		S(1)		16,671	D	$6.0702(2)	15,353,338	I	See footnote(3)
Common Stock	10/16/2025		S(1)		12,844	D	$6.1014(4)	15,340,494	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

SVF Endurance (Cayman) Ltd

(Last) (First) (Middle)

C/O WALKERS CORP LTD., 190 ELGIN AVENUE

(Street)

GEORGE TOWN E9 KY1-9008

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

SOFTBANK VISION FUND (AIV M1) L.P.

(Last) (First) (Middle)

1521 CONCORD PIKE

(Street)

WILMINGTON, DE 19803

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

SB INVESTMENT ADVISERS (UK) LTD

(Last) (First) (Middle)

69 GROSVENOR STREET

(Street)

LONDON, X0 W1K 3JP

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.07 to $6.0765. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.07 to $6.1451. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	SVF Endurance (Cayman) Limited, By: /s/ Nilani Perera, Director	10/17/2025
	SoftBank Vision Fund (AIV M1) L.P., By: SB Investment Advisers (UK) Limited, its manager, By: /s/ Amanda Sanchez-Barry, General Counsel	10/17/2025
	SB Investment Advisers (UK) Limited, By: /s/ Amanda Sanchez-Barry, General Counsel	10/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did VIR’s Form 4 report for SVF Endurance (Cayman) Limited?

Two open‑market sales under a Rule 10b5‑1 plan and updated indirect beneficial holdings.

How many VIR shares were sold and at what prices?

16,671 shares at a weighted average of $6.0702 on 10/15/2025 and 12,844 shares at $6.1014 on 10/16/2025.

What are the indirect beneficial holdings after the trades for VIR?

Indirect beneficial ownership is reported as 15,340,494 shares after the transactions.

Was the sale conducted under a Rule 10b5-1 plan for VIR?

Yes. The sales were effected pursuant to a Rule 10b5‑1 trading plan entered on September 3, 2025.

Who is the reporting person in the VIR Form 4?

SVF Endurance (Cayman) Limited, a subsidiary of SoftBank Vision Fund (AIV M1) L.P., with SB Investment Advisers (UK) Limited as AIFM.

Did the Form 4 disclose price ranges for the sales?

Yes. The filing lists weighted‑average prices and states the shares were sold in ranges, with full breakdowns available upon request.